Applied Biosystems and SAIC-Frederick, Inc. to Collaborate on NCI-Funded Genotyping Studies for Cancer Research
Applied Biosystems (NYSE:ABI), an Applera Corporation business, today announced at the 2006 Annual Meeting of the American Association for Cancer Research (AACR) that it has entered into a collaboration with the Core Genotyping Facility, SAIC-Frederick, Inc., a contractor for the National Cancer Institute (NCI), on a series of biomarker studies for cancer research.
The NCI-funded Core Genotyping Facility will use Applied Biosystems’ entire TaqMan(R) Drug Metabolism Genotyping Assay collection to examine genetic variations in the HapMap and SNP500Cancer samples in order to validate additional cancer biomarkers.
In support of the NCI, the Core Genotyping Facility is using more than 2,400 TaqMan Drug Metabolism Genotyping Assays to generate the genotypes for samples from the International HapMap Project and from NCI’s SNP500Cancer standard sample panel. In addition, select assays with significant correlation from data analysis will be used to genotype individuals who participated in a pharmacogenetic study at the NCI evaluating treatment for Non-Hodgkin lymphoma.